What is being called "Paxlovid rebound" is not uncommon. In fact, President Biden experienced just this after a course of the drug. What should be done? Drs. Henry Miller and Josh Bloom discuss just this.
Emergency Use Authorization
Cato Institute's Dr. Jeff Singer (also a member of the ACSH Scientific Advisory Board) is none too pleased with both the CDC and FDA and the way they've handled monkeypox. It seems lessons from COVID-19 have gone unlearned.
Finally, there are antiviral drugs that will keep people with COVID out of the hospital (and the morgue). But, good luck getting a prescription if you should need it. The FDA has pretty much guaranteed that this will be almost impossible. Here's why.
It was pretty much a forgone conclusion, but the FDA's decision to grant an Emergency Use Authorization to Pfizer's COVID drug, Paxlovid, could mark the turning point in our battle against the virus. Here's the story that you won't find anywhere in the press.
What happens when politics and science mix? Scary stuff. Dr. Henry Miller examines the considerable downside of releasing any COVID vaccine prior to the completion of Phase 3 trials. The founding director of the FDA's Office of Biotechnology, Dr. Miller argues that precise science, not the date of an election, is critical at this time.
For everything, there is a time and place. Emergency Use Authorizations by the FDA were necessary for COVID-19's recent past; they are not necessary and will be harmful when applied to a COVID-19 vaccine.